Chemomab Therapeutics annual r&d spending
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Chemomab Therapeutics R&D Spending Growth & History (CMMB)
Chemomab Therapeutics's r&d spending was $5.8M for fiscal 2025.
View full Chemomab Therapeutics company overviewChemomab Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.8M | −$5.5M | −48.50% |
| 2024 | 2024-12-31 | $11.3M | −$7.1M | −38.38% |
| 2023 | 2023-12-31 | $18.4M | $1.4M | +8.27% |
| 2022 | 2022-12-31 | $17.0M | $10.6M | +168.03% |
| 2021 | 2021-12-31 | $6.3M | $1.6M | +35.23% |
| 2020 | 2020-12-31 | $4.7M | −$8.6M | −64.79% |
| 2019 | 2019-12-31 | $13.3M | $5.8M | +77.04% |
| 2018 | 2018-12-31 | $7.5M | $1.3M | +20.63% |
| 2017 | 2017-12-31 | $6.2M | $3.8M | +161.28% |
| 2016 | 2016-12-31 | $2.4M | — | — |
Chemomab Therapeutics quarterly r&d spending
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q2.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.1M | −$145,000 | −11.27% |
| Q1 2026 | 2026-03-31 | $925,000 | −$1.6M | −62.90% |
| Q4 2025 | 2025-12-31 | $1.1M | — | — |
| Q3 2025 | 2025-09-30 | $960,000 | — | — |
| Q2 2025 | 2025-06-30 | $1.3M | −$1.6M | −56.05% |
| Q1 2025 | 2025-03-31 | $2.5M | — | — |
| Q2 2024 | 2024-06-30 | $2.9M | −$2.1M | −41.67% |
| Q2 2023 | 2023-06-30 | $5.0M | $2.1M | +72.27% |
| Q1 2023 | 2023-03-31 | $6.9M | $4.1M | +150.89% |
| Q4 2022 | 2022-12-31 | $5.9M | $3.5M | +147.38% |
| Q3 2022 | 2022-09-30 | $5.4M | $3.9M | +264.69% |
| Q2 2022 | 2022-06-30 | $2.9M | $1.6M | +122.95% |
| Q1 2022 | 2022-03-31 | $2.7M | $1.6M | +137.25% |
| Q4 2021 | 2021-12-31 | $2.4M | $1.1M | +90.03% |
| Q3 2021 | 2021-09-30 | $1.5M | $456,000 | +44.23% |
| Q2 2021 | 2021-06-30 | $1.3M | $460,000 | +54.31% |
| Q1 2021 | 2021-03-31 | $1.2M | −$395,000 | −25.45% |
| Q4 2020 | 2020-12-31 | $1.3M | $227,000 | +22.10% |
| Q3 2020 | 2020-09-30 | $1.0M | −$4.5M | −81.47% |
| Q2 2020 | 2020-06-30 | $847,000 | −$1.7M | −67.12% |
| Q1 2020 | 2020-03-31 | $1.6M | −$2.6M | −62.47% |
| Q4 2019 | 2019-12-31 | $1.0M | — | — |
| Q3 2019 | 2019-09-30 | $5.6M | — | — |
| Q2 2019 | 2019-06-30 | $2.6M | — | — |
| Q1 2019 | 2019-03-31 | $4.1M | — | — |
Chemomab Therapeutics r&d spending trends
Over the last five fiscal years, Chemomab Therapeutics's r&d spending increased from $4.7M to $5.8M, a change of $1.1M. The latest reported quarter, Q2 2026, shows $1.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Chemomab Therapeutics source filings ↗